Completed PHASE1 INTERVENTIONAL 2-arm NCT06517485

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

A Phase 1b/2, First-in-Human, Dose Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

Sponsor: Mersana Therapeutics

Conditions Non-Small Cell Adenocarcinoma Platinum Resistant Ovarian Cancer

Updated 2 times since 2024 Last updated: Jul 18, 2024 Started: Jul 30, 2019 Primary completion: May 31, 2022 Completion: Aug 3, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non-Small Cell Adenocarcinoma and Platinum Resistant Ovarian Cancer and is currently completed. Mersana Therapeutics leads this study, which shows 2 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mersana Therapeutics

Data source: Mersana Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oklahoma City, United States